Prognostic Factors in Diffuse Large Bcell Lymphoma Treated by Riskadopted Therapy

Prognostic factors in diffuse large B-cell lymphoma.

To Rami, Alfons and Mimi " It does not matter how slowly you go as long as you do not stop. " – Confucius VII

Primary Diffuse Large Bcell Lymphoma of the Humerus. Case Report and Review of Literature

Situated among the rare bone tumors, the primary di use large B-cell lymphoma occupies a well-worth place in doctor’s attention given the di culty of diagnosis and the speci c treatment, as well as the high lay time in showing of the clinical features. Biopsy followed by imunohistochemistry is the gold standard in investigations. e presentation that follows shows a rare case of the primary di u...

Salvage therapy for diffuse large-cell lymphoma.

Biological prognostic markers in diffuse large B-cell lymphoma.

BACKGROUND Multiple novel therapeutic options have emerged in the treatment of non-Hodgkin lymphoma, including monoclonal antibodies and different classes of biological agents. With this increased diagnostic sophistication, novel prognostic markers are needed to stratify patients according to risk factors, particularly those with a mechanistic underpinning, to provide the basis for individually...

Prognostic biomarkers in diffuse large B-cell lymphoma.

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. Although it represents a curable disease, less than half of the patients are cured with conventional chemotherapy. The highly variable outcome reflects a heterogeneous group of tumors, with different genetic abnormalities and response to therapy. The International Prognostic Index (IPI) is useful in predict...